<DOC>
	<DOCNO>NCT02840162</DOCNO>
	<brief_summary>This study seek determine downstream effect cyclooxygenase-2 ( COX-2 ) inhibition suggest preclinical system occur human prostate cancer . To answer question , men choose prostatectomy randomly assign preoperative treatment celecoxib placebo four week . Carefully collected tumor , premalignant , benign prostate tissue examine apoptosis , androgen receptor prostaglandin E2 level . Tumor COX-2 expression correlate observed treatment effect . The data generate study serve foundation development COX-2 target therapy prostate cancer , provide preliminary evidence large scale clinical trial aim treatment prevention prostate cancer , validate current preclinical model use study COX-2 prostate cancer .</brief_summary>
	<brief_title>Pre-Prostatectomy Celecoxib Placebo</brief_title>
	<detailed_description>PRIMARY OBJECTIVE I . To determine COX-2 inhibition celecoxib significantly increase apoptosis human adenocarcinoma prostate . SECONDARY OBJECTIVES I . To determine COX-2 inhibition celecoxib reduces level Prostaglandin E2 androgen receptor fresh tumor tissue collect prostatectomy II . To collect pre- postoperative serum Prostate Specific Antigen ( PSA ) exploratory analyse III . To determine effect celecoxib adverse effect , perioperative surgical complication post surgery analgesic use</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Benzenesulfonamide</mesh_term>
	<criteria>Histopathologically cytologically proven adenocarcinoma prostate plan prostatectomy Age &gt; = 18 Performance status ( ECOG &lt; = 2 ) Hemoglobin &gt; 10 g/dL ( within 4 week ) Creatinine &lt; = 1.5 mg/dL Signed informed patient consent Other preoperative prior treatment direct prostate cancer Significant active medical illness opinion investigator would preclude protocol treatment Use nonsteroidal antiinflammatory agent within seven day celecoxib treatment Hypersensitivity celecoxib A history asthma , urticaria , anaphylaxis precipitate NSAID History significant upper gastrointestinal bleed active peptic ulcer disease Current treatment anticoagulant Allergy sulfonamide</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>NSAIDs</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>celecoxib</keyword>
	<keyword>COX-2 inhibitor</keyword>
</DOC>